Norbexi Industries Limited has announced the complete divestment of its shareholding in Bacil Pharma Limited, filing a disclosure under Regulation 29(2) of SEBI's Substantial Acquisition of Shares and Takeover Regulations, 2011. The transaction represents a significant corporate development as the company has completely exited its investment in the pharmaceutical firm.

Transaction Details

The divestment involved the sale of Norbexi Industries' entire stake in Bacil Pharma Limited through an off-market transaction executed on February 19, 2026. The disclosure, submitted to the Bombay Stock Exchange on February 21, 2026, provides comprehensive details of the shareholding changes.

Shareholding Analysis

Prior to this transaction, Norbexi Industries held a substantial position in Bacil Pharma Limited. The company's shareholding pattern has undergone a complete transformation following this divestment.

Corporate Structure

Norbexi Industries Limited, formerly known as GB Hospitality (India) Private Limited, is incorporated with CIN U52292MH2016PTC273960 and headquartered in Nagpur, Maharashtra. The disclosure was signed by Director Prashant Natwarlal Lakhani (DIN: 00559519), confirming the company's complete exit from Bacil Pharma Limited.

Bacil Pharma Limited maintains its equity structure with 14,353,000 equity shares of ₹10 each, and the company's shares continue to be listed on the Bombay Stock Exchange Limited. The divestment by Norbexi Industries does not impact Bacil Pharma's total share capital, which remains unchanged at 14,353,000 equity shares.

Regulatory Compliance

The transaction disclosure fulfills the requirements under SEBI regulations for substantial acquisition and disposal of shares. Norbexi Industries has confirmed that it does not belong to the promoter or promoter group of Bacil Pharma Limited, indicating this was a strategic investment that has now been completely liquidated.

Bacil Pharma Limited has announced its unaudited financial results for the quarter ended December 31, 2025, demonstrating a significant turnaround in its financial performance. The Board of Directors approved these results during their meeting held on February 13, 2026, at the company's registered office.

Financial Performance Highlights

The company's Q3FY26 results show a remarkable improvement across key financial metrics compared to the same period last year.

Nine-Month Performance Analysis

The nine-month period ended December 31, 2025, also reflected strong performance improvements for the pharmaceutical company.

Revenue and Expense Structure

The company's revenue structure remained consistent with previous periods, with total revenue comprising entirely of other income at ₹6.45 lakhs for Q3FY26. Revenue from operations remained nil during the quarter.

Expense management showed significant improvement:

• Employee benefits expense: ₹0.60 lakhs (Q3FY26) vs ₹3.90 lakhs (Q3FY25)
• Other expenses: ₹1.93 lakhs (Q3FY26) vs ₹2.60 lakhs (Q3FY25)
• Total expenses: ₹2.53 lakhs (Q3FY26) vs ₹6.50 lakhs (Q3FY25)

Other Comprehensive Income

The company reported other comprehensive income of ₹2.18 lakhs in Q3FY26, primarily from gains on fair valuation of financial assets. This contributed to a total comprehensive income of ₹6.10 lakhs for the quarter, compared to a loss of ₹6.20 lakhs in Q3FY25.

Capital Structure

Bacil Pharma's paid-up equity share capital stood at ₹1,397.03 lakhs as of December 31, 2025, with a face value of ₹10 per share. This represents a significant increase from ₹589.00 lakhs in the corresponding period last year.

Auditor's Review

The financial results were reviewed by Sarang Shivajirao Chavan and Associates, Chartered Accountants. The auditors issued a limited review report with several emphasis of matter points, including concerns about fund utilization from preferential allotment and compliance with certain statutory requirements under GST and Income Tax Acts.

Source: